Last reviewed · How we verify

Mycobacterium w immunotherapy — Competitive Intelligence Brief

Mycobacterium w immunotherapy (Mycobacterium w immunotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mycobacterial immunotherapy. Area: Oncology.

phase 3 Mycobacterial immunotherapy Oncology Biologic Live · refreshed every 30 min

Target snapshot

Mycobacterium w immunotherapy (Mycobacterium w immunotherapy) — University of Cape Town. Mycobacterium w is a heat-killed mycobacterial immunotherapy that stimulates innate and adaptive immune responses to enhance anti-tumor immunity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mycobacterium w immunotherapy TARGET Mycobacterium w immunotherapy University of Cape Town phase 3 Mycobacterial immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mycobacterial immunotherapy class)

  1. University of Cape Town · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mycobacterium w immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/mycobacterium-w-immunotherapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: